Allogeneic stem cell transplantation for thalassemia major in India

Mathews, Vikram ; Balasubramanian, Poonkuzhali ; Abraham, Aby ; George, Biju ; Srivastava, Alok (2017) Allogeneic stem cell transplantation for thalassemia major in India Pediatric Hematology Oncology Journal, 2 (4). pp. 114-120. ISSN 2468-1245

Full text not available from this repository.

Official URL:

Related URL:


Allogeneic stem cell transplantation (allo-SCT) is the only currently available curative treatment for thalassemia major. Since it was first done in 1981, several thousand patients have benefited from it and it is now possible to offer this treatment in different parts of the world with good results. With better risk stratification and supportive care, the results of allo-SCT are now very good even in high risk patients who have significant iron overload related organ dysfunction. The improvements have mainly been in the conditioning strategies with less toxic myeloablation and management of the complications of SCT. However, several challenges remain. Transplant related complications still cause significant morbidity and mortality. There is data to show that the results of transplantation as best if done in well transfused and chelated patients <7 years of age. As only a third of the patients will have a matched related donor, there is need for investigating SCT with alternative donors. Experience with SCT for thalassemia major from matched unrelated donors or haplo-identical donors is still limited but needs further exploration. Adequate management needs to be provided post-SCT for all pre-existing complications particularly iron chelation to prevent further organ dysfunction. Systematic follow-up is needed to measure long term outcomes. The biggest challenges in India are the cost of this treatment and access to centres capable of providing this treatment. With greater support from the government, health insurance and philanthropic programs, there has been a rapid increase in the number of SCTs for thalassemia major in India. The number centres providing this treatment are also increasing making this curative treatment more widely available in India.

Item Type:Article
Source:Copyright of this article belongs to Elsevier Science.
Keywords:Thalassemia Major; Allogeneic Stem Cell Transplant; Conditioning Regimens; Regimen Related Toxicity; Alternative Donors
ID Code:114006
Deposited On:07 Jun 2018 11:18
Last Modified:07 Jun 2018 12:14

Repository Staff Only: item control page